Rain Therapeutics headlines newest slate of IPO-bound biotechs with $100M penciled in for lead oncology program

A fresh slate of biotech IPOs has filed to go public as the calendar turns toward the second quarter.

Three companies filed their registrational paperwork over the holiday weekend, with Rain Therapeutics and Impel NeuroPharma submitting S-1s on Friday and Anebulo Pharmaceuticals doing so last Thursday. Rain leads the estimated raises of the group with a $100 million tranche penciled in, followed by Impel at $75 million and Anebulo at a modest $15 million.